Thromb Haemost 1985; 53(02): 200-203
DOI: 10.1055/s-0038-1661273
Original Article
Schattauer GmbH Stuttgart

In Vitro Studies on the Fibrinolytic, Thrombolytic and Fibrinogenolytic Properties of a Tissue Plasminogen Activator from Guinea Pig Keratocytes

A Electricwala
1   The Microbial Technology Laboratory, PHLS Centre for Applied Microbiology and Research, Salisbury, Wiltshire, UK
,
R J Ling
1   The Microbial Technology Laboratory, PHLS Centre for Applied Microbiology and Research, Salisbury, Wiltshire, UK
,
P M Sutton
1   The Microbial Technology Laboratory, PHLS Centre for Applied Microbiology and Research, Salisbury, Wiltshire, UK
,
B Griffiths
2   The Vaccine Research and Production Laboratory, PHLS Centre for Applied Microbiology and Research, Salisbury, Wiltshire, UK
,
P A Riley
3   The Department of Biochemical Pathology, School of Medicine, University College, London, UK
,
T Atkinson
1   The Microbial Technology Laboratory, PHLS Centre for Applied Microbiology and Research, Salisbury, Wiltshire, UK
› Author Affiliations
Further Information

Publication History

Received 11 October 1984

Accepted 19 December 1984

Publication Date:
18 July 2018 (online)

Summary

The fibrinolytic and thrombolytic properties of a tissue plasminogen activator (tPA) purified from the conditioned medium of an established guinea pig keratocyte (GPK) cell line were investigated in in vitro systems and compared with urokinase. Using the fibrin clot lysis assay, GPK activator appears to be similar to human melanoma tPA and not to human urokinase. GPK activator also caused negligible fibrinogen breakdown, when incubated with human plasma at 37° C over 23 hr. Urokinase on the other hand caused significant fibrinogenolysis, under similar conditions. Comparison of the lysis of plasma clots by GPK activator and human urokinase have shown that GPK activator was a much more effective fibrinolytic agent than urokinase, especially at lower concentrations (<50 IU/ml). Studies on the thrombolytic effect of GPK activator on the lysis of aged and cross-linked whole human blood clots and plasma clots hanging in artificially circulating human plasma suggest that GPK activator can lyse both these types of clots equally well. The lysis is dose dependent, attaining complete lysis within 3–6 hr with the concentration of GPK activator in the range of 1–5 μg/ml plasma. It is concluded that GPK activator has a higher fibrinolytic and thrombolytic activity and lower fibrinogenolytic activity than urokinase.

 
  • References

  • 1 Hoylaert M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin J Biol Chem 1982; 257: 2912-2919
  • 2 Collen D. On the regulation of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
  • 3 Rijken DC, Collen D. Purification and characterisation of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
  • 4 Wallen P, Pohl E, Bergsdorf N, Ranby M, Ny T, Jornvall H. Purification and characterisation of a melanoma cell plasminogen activator. Eur J Biol 1983; 132: 681-686
  • 5 Rijken DC, Hoylaert M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic plasminogen activator. J Biol Chem 1982; 257: 2929-2935
  • 6 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemostas 1981; 45: 225-229
  • 7 Komingen C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic plasminogen activator in human blood and in various animal species in vitro. Thromb Haemostas 1981; 46: 561-565
  • 8 Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic plasminogen activator in rabbits with experimental jugular vein thrombosis. J Clin Invest 1983; 71: 368-376
  • 9 Weiman W, Stibbe J, Van Seyer AJ, Billian A, De Somer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic plasminogen activator. Lancet 1981; 2: 1018-1020
  • 10 Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA A, De Geest H, Verstraete M, Collen D, Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Eng J Med 1984; 310: 609-613
  • 11 Atkinson T, Electricwala A, Latter A, Riley PA, Sutton PM. New tissue sources and types of fibrinolytic enzymes. Lancet 1982; 2: 132-133
  • 12 Electricwala A, Riley PA, Latter A, Sutton PM, Atkinson T. New fibrinolytic enzymes from epithelial cells. In Progress in Fibrinolysis. Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. (Eds) Churchill Livingstone; Edinburgh, London, Melbourne, New York: 1983. VI 151-153
  • 13 Electricwala A, Sutton PM, Griffiths B, Riley PA, Latter A, Atkinson T. Purification and properties of the plasminogen activator secreted by guinea pig keratocyte cells in culture. In Clinical Aspects of Fibrinolysis and Thrombolysis. Jespersen J, Kluft C, Korsgaad O. (Eds) South Jutland University Press; Esberg, Denmark: 1983. pp 85-91
  • 14 Electricwala A, Sutton PM, Griffiths B, Riley PA, Atkinson T. Comparison of the properties of epithelial with other tissue type plasminogen activators. Haemostasis 1984; 14: 50
  • 15 Electricwala A, Atkinson T. Purification and properties of plasminogen activators from epithelial cells. Eur J Biochem (in press).
  • 16 Gaffney PJ, Templeman J, Curtis AD, Campbell PJ. The stability of tissue-plasminogen activator. Thromb Haemostas 1983; 50: 650-651